Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.38 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834186 | 0.89 | HIF1A (0.49) | ALBHIF1APRSS12KAT6APTPN1 | |
| SCHEMBL6835695 | 0.86 | ALB (0.46) | ALBHIF1ASIRT2 | |
| SCHEMBL6817726 | 0.86 | HIF1A (0.41) | ALBHIF1APRSS12 | |
| SCHEMBL6819451 | 0.86 | ALB (0.45) | ALBPRSS12KITKAT6ASIRT2 | |
| SCHEMBL6830338 | 0.85 | ALB (0.47) | ALBHIF1AKAT6A | |
| SCHEMBL6830645 | 0.85 | ALB (0.48) | ALBHIF1APRSS12 | |
| SCHEMBL7158818 | 0.85 | ALB (0.46) | ALBHIF1A | |
| SCHEMBL6818893 | 0.84 | ALDH1A1 (0.49) | ALB | |
| SCHEMBL6834064 | 0.84 | ALB (0.42) | ALBHIF1A | |
| SCHEMBL6833090 | 0.83 | ALB (0.43) | ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALB 1417/4885HIF1A 220/4885PRSS12 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.